Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 4.7%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares fell 4.7% on Monday . The stock traded as low as $44.29 and last traded at $44.77. 258,483 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 2,733,259 shares. The stock had previously closed at $46.99.

Analysts Set New Price Targets

A number of equities analysts have commented on APLS shares. UBS Group boosted their price target on shares of Apellis Pharmaceuticals from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, August 23rd. Wells Fargo & Company raised Apellis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $34.00 to $64.00 in a report on Friday, September 15th. Needham & Company LLC raised their price target on Apellis Pharmaceuticals from $60.00 to $63.00 and gave the company a “buy” rating in a report on Wednesday, November 1st. Robert W. Baird reduced their price objective on Apellis Pharmaceuticals from $115.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 1st. Finally, Citigroup increased their target price on Apellis Pharmaceuticals from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, October 6th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $66.50.

Apellis Pharmaceuticals Trading Up 5.2 %

The business’s 50 day simple moving average is $44.77 and its 200-day simple moving average is $58.69. The company has a quick ratio of 3.76, a current ratio of 4.29 and a debt-to-equity ratio of 0.40.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.29). Apellis Pharmaceuticals had a negative net margin of 222.16% and a negative return on equity of 209.10%. The company had revenue of $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. During the same quarter in the prior year, the company posted ($1.75) EPS. The company’s revenue for the quarter was up 400.5% compared to the same quarter last year. As a group, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -4.59 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $45.34, for a total value of $56,675.00. Following the completion of the sale, the director now owns 367,420 shares of the company’s stock, valued at $16,658,822.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $45.34, for a total value of $56,675.00. Following the completion of the sale, the director now owns 367,420 shares in the company, valued at approximately $16,658,822.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Cedric Francois sold 150,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $41.75, for a total value of $6,262,500.00. Following the transaction, the chief executive officer now owns 424,655 shares in the company, valued at $17,729,346.25. The disclosure for this sale can be found here. Insiders have sold 210,914 shares of company stock worth $8,938,011 in the last ninety days. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of APLS. First Horizon Advisors Inc. increased its position in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares in the last quarter. Clearstead Advisors LLC bought a new position in shares of Apellis Pharmaceuticals during the 1st quarter worth approximately $27,000. Covestor Ltd raised its holdings in shares of Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after purchasing an additional 677 shares during the last quarter. National Bank of Canada FI bought a new stake in Apellis Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Stephens Consulting LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth about $38,000. 90.43% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).